Unither Pharmaceuticals Overview
- Year Founded
-
1993
- Status
-
Private
- Employees
-
2,300
- Latest Deal Type
-
Debt Refin.
- Financing Rounds
-
8
- Investments
-
10
Unither Pharmaceuticals General Information
Description
Provider of pharmaceutical-based contract manufacturing services intended for the healthcare and generic drug industry. The company specializes in the manufacture and packaging of sterile unit doses, non-sterile liquids, and solid and semi-solid medications with the help of blow-fill-seal (BFS) and liquid stick-packs technologies, as well as providing regulatory expertise, galenic development, and analytical services, thereby helping its clients to increasingly outsource the manufacture of their products.
Contact Information
Website
www.unither-pharma.comCorporate Office
- Espace Industriel Nord
- 151 Rue André Durouchez CS 28028
- 80084 Amiens
- France
Corporate Office
- Espace Industriel Nord
- 151 Rue André Durouchez CS 28028
- 80084 Amiens
- France
Unither Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Unither Pharmaceuticals Comparisons
Industry
Financing
Details
Unither Pharmaceuticals Competitors (16)
One of Unither Pharmaceuticals’s 16 competitors is Alcami, a Private Equity-Backed company based in Wilmington, NC.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alcami | Private Equity-Backed | Wilmington, NC | ||||
| Pnp Pharmaceuticals | Private Equity-Backed | Burnaby, Canada | ||||
| Recipharm | Private Equity-Backed | Stockholm, Sweden | ||||
| Bend Bioscience (Formerly CoreRx) | Private Equity-Backed | Clearwater, FL | ||||
| PCI Pharma Services | Private Equity-Backed | Philadelphia, PA |
Unither Pharmaceuticals Patents
Unither Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4623919-A1 | Composition comprising iota-carrageenan for the treatment of dry eyes, non-viral conjunctivitis and allergic ocular conditions | Pending | 28-Mar-2024 | ||
| AU-2025246042-A1 | Composition comprising iota-carrageenan for use in the treatment of dry eyes, non-viral and non-allergic eye conditions | Pending | 28-Mar-2024 | ||
| FR-3154024-A1 | Nasal spray and nasal spray method | Pending | 16-Oct-2023 | ||
| EP-4541396-A1 | Nasal sprayer and method for loading the nasal sprayer | Active | 16-Oct-2023 | ||
| EP-4541396-B1 | Nasal sprayer and method for loading the nasal sprayer | Active | 16-Oct-2023 | A61M15/08 |
Unither Pharmaceuticals Signals
Unither Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Unither Pharmaceuticals Investments (10)
Unither Pharmaceuticals’s most recent deal was a Buyout/LBO with Carragelose for . The deal was made on 28-Feb-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Carragelose | 28-Feb-2025 | Buyout/LBO | Drug Discovery | ||
| BIOPHTA | 01-Jun-2024 | Seed Round | Drug Delivery | ||
| Novartis (Plant in São Paulo) | 28-Nov-2022 | Buyout/LBO | Buildings and Property | ||
| Curecall | 13-Jul-2022 | Early Stage VC | Medical Records Systems | ||
| Curecall | 21-Oct-2020 | Seed Round | Medical Records Systems |
Unither Pharmaceuticals Exits (3)
Unither Pharmaceuticals’s most recent exit was on 13-Jul-2022 from Curecall. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Curecall | 13-Jul-2022 | Completed |
|
||
| Curecall | 21-Oct-2020 | Completed |
|
||
| Créapharm Group | 24-Nov-2005 | Buyout/LBO | Completed |
|
Unither Pharmaceuticals Affiliates
Subsidiaries (4)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Unither Liquid Manufacturing | Colomiers, France | 2008 | |
| Unither Industries | Gannat, France | 2008 | |
| Carragelose | Korneuburg, Austria | 2007 | |
| Unither Developpement Bordeaux | Le Haillan, France | 2006 |
Unither Pharmaceuticals FAQs
-
When was Unither Pharmaceuticals founded?
Unither Pharmaceuticals was founded in 1993.
-
Where is Unither Pharmaceuticals headquartered?
Unither Pharmaceuticals is headquartered in Amiens, France.
-
What is the size of Unither Pharmaceuticals?
Unither Pharmaceuticals has 2,300 total employees.
-
What industry is Unither Pharmaceuticals in?
Unither Pharmaceuticals’s primary industry is BPO/Outsource Services.
-
Is Unither Pharmaceuticals a private or public company?
Unither Pharmaceuticals is a Private company.
-
What is Unither Pharmaceuticals’s current revenue?
The current revenue for Unither Pharmaceuticals is .
-
How much funding has Unither Pharmaceuticals raised over time?
Unither Pharmaceuticals has raised $381M.
-
Who are Unither Pharmaceuticals’s investors?
GIC Private, IK Partners, NiXEN Partners, Keensight Capital, and Parquest Capital are 5 of 6 investors who have invested in Unither Pharmaceuticals.
-
Who are Unither Pharmaceuticals’s competitors?
Alcami, Pnp Pharmaceuticals, Recipharm, Bend Bioscience (Formerly CoreRx), and PCI Pharma Services are some of the 16 competitors of Unither Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process